ReadyCell is a biotechnological company focused on providing sophisticated in vitro tools and R&D services for the ADME-Tox segment.
Our tools are innovative cell-based and ready-to-use kits for efficacy and safety testing of active molecules as an alternative to animal testing, on drug discovery.
The current product portfolio covers a a wide spectrum of drug discovery applications for in vitro screening, including adsorption, metabolism and toxicity assays.
The goal of our products is to provide robust and reliable results in a fast and efficient manner, reducing user’s time and costs, and allowing pharmaceutical and biotech companies to use human and material resources more efficiently, while optimizing the development cycle for new drugs.
ReadyCell develops, implements and commercializes new innovative kits through strategic partnership with other emerging market players: Biotechnological, pharmaceutical & Med Dev companies and Research Centers.
Our R&D department works intensively in the expansion of our product portfolio, with the aim of developing new tools that fulfill the needs of the pharmaceutical industry. By offering a diversity of R&D service, we put at the industry disposal our expertise, know-how, technical & human resources to develop ad hoc solutions according to their specific needs.
In 2010, Advancell’s alternative testing unit is segregated from the core company, as part of a new business strategy aimed to refocus the company’s activity into the nano medicine and drug development fields.
At that time, Technological LEITAT center was intensively involved in increasing its portfolio of services and products within the biotechnology and biomedicine field.
Thus, Readycell was established in 2011 as a joint venture, equally owned by Advancell and Technological LEITAT group, aimed to develop and commercialize cell-based reagents and offer R&D services in the field ADME-Tox.
This corporate operation would allow to combine the vast know-how and expertise, along with technical and human resources of two entities in the biotechnology field, and take advantage of synergies, to create a highly competitive company aimed to:
- Improve and commercialize the product portfolio of Advancell’s alternative testing unit.
- Iniciate new research projects to develop new kits and services.
From 2014, ReadyCell is fully part of Leitat structure. Whitin this environment, ReadyCell completely integrates its R&D Management and Commercial effort in its mother company matrix, thus allowing us to develop more complex projects, to participate in more dissemination events and to be more visible, thus in turn offering the highest quality service to our customers in the field of in vitro ADME assays.